EXEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EXEL is a good buy for a beginner with a long-term horizon and $50,000-$100,000 available, but it should be approached as a measured long-term position rather than an aggressive bet. The stock is in a constructive technical uptrend, sentiment from options is mildly bullish, and recent analyst target moves are still clustered around the mid-$40s to mid-$50s, which is broadly aligned with the current price. Given the lack of recent negative news, neutral insider/hedge fund activity, and no concerning congress trading signals, the setup is favorable enough to buy now for a long-term investor who does not want to wait for a perfect pullback.
EXEL is showing a bullish short-to-medium-term technical structure. The stock closed at 55.56, just under the reported R1 resistance at 55.536 and near the upper end of the recent range. MACD histogram is positive and expanding, which supports momentum continuation. The moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), indicating trend strength across multiple timeframes. RSI_6 at 75.558 is elevated, suggesting the stock is extended in the near term, but not enough to negate the broader uptrend. Key levels: pivot 53.469, support 51.402, resistance 56.812. Overall trend remains positive.
["No negative news in the recent week, which keeps the setup clean.", "Bullish technical trend with SMA_5 > SMA_20 > SMA_200 and expanding positive MACD.", "Analyst targets have recently been raised by UBS, H.C. Wainwright, and TD Cowen, showing continued interest in the name.", "The stock has recent estimated upside momentum in pattern analysis, with a positive next-week and next-month drift profile.", "No significant insider selling, hedge fund pressure, or recent congress trading activity was reported."]
["Truist downgraded the stock to Hold and cited risk from the recent zanzalintinib topline miss.", "Cabometyx is nearing maturity, which raises dependence on future pipeline progress.", "RSI is elevated, so the stock is somewhat extended after the recent move.", "Wall Street views remain mixed, with several Neutral/Equal Weight/Hold ratings still in place."]
No usable latest-quarter financial snapshot was provided because the financial data returned an error. Based on the information available, the most relevant fundamental takeaway is that analysts are still focused on pipeline development and the transition beyond Cabometyx. Because the latest quarter season and growth figures were not provided, there is not enough financial evidence here to assess recent revenue or earnings acceleration.
Analyst sentiment is mixed but slightly constructive. UBS raised its target to $52 and kept Neutral; Truist downgraded to Hold with a $54 target; H.C. Wainwright remains Buy at $56; TD Cowen remains Buy at $55; Stifel is Hold at $47; Morgan Stanley is Equal Weight at $50; Barclays is Equal Weight at $45. The overall Wall Street view is balanced rather than strongly bullish, with pros centered on resilience and pipeline optionality, and cons centered on pipeline execution risk and Cabometyx maturity. The recent target revisions have generally drifted upward, but ratings remain split.
